As shown in Figures 1(a) and 1(b), the independent-sample t-test indicated that de novo non-M3 AML patients showed a higher intensity of the CD56 expression compared with ALL (P = 0.017) or the healthy controls (normal BM) (P = 0.02). The gene discussed is NCAM1; the disease is acute lymphoblastic leukemia.